When ‘Right to Try’ Isn’t Enough: Congress Wants a Single ALS Patient to Get a Therapy Never Tested in Humans

June 3, 2019

(STAT News) – The Hermstads’ progress reopens an ardent debate in Washington over the FDA’s role in determining when sick or dying patients can access experimental therapies — and what role career politicians should play in the nation’s decisions about how and when to let patients access untested treatments. It also underscores a fundamental question about the role of lawmakers: Is it fair for a member of Congress to intervene on behalf of a single constituent?

Recommended Reading